PE-22-28 is a synthetic heptapeptide fragment derived from spadin; a naturally occurring peptide cleaved from the propeptide of the sortilin receptor. First synthesized in 2017 as a shorter, more potent analogue of spadin. Hudson Science’s formulation supplies 10mg as a lyophilized vial, preserving peptide structural integrity across storage conditions until reconstitution. PE-22-28 is documented as the shortest, most efficient sequence capable of blocking the TREK-1 channel with higher potency than spadin.
PE-22-28’s primary mechanism of action centers on blocking TREK-1 (TWIK related K+ channel 1), a two pore domain potassium channel widely expressed in the central nervous system playing a role in pain perception, mood regulation, and neuroprotection. TREK-1 channel inhibition reduces background potassium current in neuronal membranes, raising membrane excitability and enhancing serotonergic transmission. Laboratory studies investigate PE-22-28’s effects on neuronal membrane properties, hippocampal neurogenesis including cell proliferation, survival and differentiation, synaptic plasticity, and depression related behaviors in preclinical models, with research demonstrating rapid onset antidepressant like effects within 4 hours in validated behavioral paradigms, contrasting with conventional antidepressants requiring chronic administration.
Emerging studies have shed light on TREK-1 over expression in post stroke depression, with experimental mouse models indicating the potential to mitigate this upregulation using TREK-1 inhibitors such as PE-22-28. Unlike SSRIs which were associated with a range of unintended side effects, PE-22-28 appeared devoid of such issues in these models, with notably faster onset of action. It is important to note that PE-22-28’s evidence base remains predominantly preclinical, with limited human clinical data currently available, it is not an approved treatment for any psychiatric or neurological condition.
Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD stocks PE-22-28 alongside Selank, Semax, and other nootropic and neuroprotective peptides, giving researchers access to complementary CNS targeted compounds from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.
Commonly researched alongside Selank and Semax in comparative neuroprotective and mood regulation peptide studies. Browse CSD’s full peptide range for complete sourcing.
